Photo by solenfeyissa from unsplash
1 Zagora S, McCluskey P. Biologic therapy for uveitis: a new beginning. Intern Med J 2019; 49: 1349–51. 2 Trivedi A, Katelaris C. The use of biologic agents in the… Click to show full abstract
1 Zagora S, McCluskey P. Biologic therapy for uveitis: a new beginning. Intern Med J 2019; 49: 1349–51. 2 Trivedi A, Katelaris C. The use of biologic agents in the management of uveitis. Intern Med J 2019; 49: 1352–63. 3 Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J et al. Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388: 1183–92. 4 Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016; 375: 932–43.
Journal Title: Internal Medicine Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!